Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchAmbavirumab/romlusevimabAmbavir../r.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Ambavirumab/romlusevimab for COVID-19
3 studies from 91 scientists
1,531 patients in 1 country
Statistically significant lower risk for viral clearance.
2 studies from 2 independent teams (both from the same country) show significant improvements.
Efficacy is variant dependent.
COVID-19 Ambavirumab/romlusevimab studies. Jun 2024. c19early.org
0 0.5 1 1.5+ All studies 11% With exclusions 56% Mortality 11% Hospitalization 48% Viral clearance 7% RCTs 56% RCT mortality 56% Early 89% Late -34% Favorsambavirumab Favorscontrol
Home   Post   Share   @CovidAnalysis   Meta AnalysisMeta   Efficacy is variant dependent. mAb use may create new variants that spread globally Focosi, Leducq, and may be associated with prolonged viral loads, clinical deterioration, and immune escape Choudhary, Günther, Leducq. Recent:
Hao
Evering
Self
Yalan.
Submit updates/corrections. Summary.
Jun 13
Covid Analysis Ambavirumab/romlusevimab for COVID-19: real-time meta analysis of 3 studies
Statistically significant lower risk is seen for viral clearance. 2 studies from 2 independent teams (both from the same country) show significant improvements. Meta analysis using the most serious outcome reported shows 11% [-154..
Apr 19
Yalan et al., BMC Pharmacology and Toxicology, doi:10.1186/s40360-024-00753-7 Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study
71% higher mortality (p=0.35), 8% higher ICU admission (p=0.8), 8% shorter hospitalization (p=0.004), and 7% faster viral clearance (p=0.004). Retrospective 340 COVID-19 patients in China showing shorter length of hospital stay and faster viral clearance with BRII-196 plus BRII-198 monoclonal antibody treatment, especially when given early. The treatment did not show efficacy fo..
Sep 6
2022
Hao et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.983505 Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults
Phase 1 RCT with 44 healthy adults showing BRII-196 and BRII-198 monoclonal antibodies, alone or in combination, were safe and well-tolerated up to the highest doses tested of 3,000 mg for single mAbs and 1500/1500 mg for the combination...
Dec 23
2021
Self et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00751-9 Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
15% higher mortality (p=0.72) and 7% improved recovery (p=0.48). RCT with 182 sotrovimab patients, 176 BRII-196+BRII-198 patients, and 178 control patients, median 8 days from symptom onset, showing no significant differences and terminated early due to futility.
Nov 1
2021
Evering et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab466.1643 Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
89% lower mortality (p=0.02), 73% lower hospitalization (p<0.0001), and 79% lower combined mortality/hospitalization (p<0.0001). RCT 837 non-hospitalized high-risk COVID-19 patients showing 78% reduction in hospitalization and death with BRII-196/BRII-198 (monoclonal antibodies). Study was terminated early. BRII-196/BRII-198 had fewer grade 3+ adverse events (3.8% ..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit